Non-phosphorylated Tyr-1248 form of human epidermal growth factor receptor 2 (HER2) predicts resistance to trastuzumab therapy and poor disease-free survival of HER2-positive breast cancer patients

AIM: To determine the predictive value of phosphorylated human epidermal growth factor receptor 2 (pHER2(Y1248)) status in breast cancer (BC) patients undergoing trastuzumab-based adjuvant therapy. METHODS: Immunohistochemical status of pHER2(Y1248), EGFR/HER1, HER3, and HER4 was determined in 124 c...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramić, Snježana, Paić, Frane, Smajlbegović, Velda, Perić Balja, Melita, Hiršl, Lea, Marton, Ingrid, Knežević, Fabijan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Croatian Medical Schools 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9086810/
https://www.ncbi.nlm.nih.gov/pubmed/35505646
http://dx.doi.org/10.3325/cmj.2022.63.126

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9086810/
https://www.ncbi.nlm.nih.gov/pubmed/35505646
http://dx.doi.org/10.3325/cmj.2022.63.126

Ejemplares similares